Cara Therapeutics (NASDAQ:CARA) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report published on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

Shares of CARA stock opened at $0.26 on Friday. The stock’s 50-day moving average is $0.31 and its 200 day moving average is $0.48. Cara Therapeutics has a 1-year low of $0.24 and a 1-year high of $1.65. The company has a market cap of $14.00 million, a P/E ratio of -0.11 and a beta of 0.70.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. The firm had revenue of $0.99 million during the quarter, compared to the consensus estimate of $1.26 million. On average, analysts anticipate that Cara Therapeutics will post -1.24 EPS for the current year.

Hedge Funds Weigh In On Cara Therapeutics

An institutional investor recently raised its position in Cara Therapeutics stock. Disciplined Growth Investors Inc. MN increased its holdings in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 6.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,935,718 shares of the biopharmaceutical company’s stock after buying an additional 120,660 shares during the quarter. Disciplined Growth Investors Inc. MN owned 3.54% of Cara Therapeutics worth $499,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.